University of Virginia Medical Center Gynecologic Oncology

Topics

• Endometrial and Cervical Cancer Treatments 241
• Ovarian cancer diagnosis and treatment 139
• Cervical Cancer and HPV Research 64
• Cancer Immunotherapy and Biomarkers 32
• Genetic factors in colorectal cancer 32
• Uterine Myomas and Treatments 29
• Cancer survivorship and care 27
• Bladder and Urothelial Cancer Treatments 21
• Prostate Cancer Diagnosis and Treatment 21
• Cancer Cells and Metastasis 17
• Colorectal Cancer Surgical Treatments 16
• PARP inhibition in cancer therapy 16

Most cited

1. Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy.

   Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022 · 795 citations · Charles Friel

2. Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial.

   Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024 · 304 citations · Charles Friel

3. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.

   Lancet (London, England) · 2024 · 348 citations · Linda Duska

4. Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.

   The New England journal of medicine · 2023 · 405 citations · Linda Duska

5. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.

   Lancet (London, England) · 2024 · 208 citations · Linda Duska

6. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.